<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950101</url>
  </required_header>
  <id_info>
    <org_study_id>HPV Study</org_study_id>
    <nct_id>NCT04950101</nct_id>
  </id_info>
  <brief_title>Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis</brief_title>
  <official_title>Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the prevalence of anal high-risk HPV infection and&#xD;
      abnormal cytology in HIV uninfected Men who have sex with men (MSM) using PrEP and HIV&#xD;
      infected MSM followed-up at the S-kliniek or HRC of the UZ Brussel. 200 participants will be&#xD;
      preferably included in the study. The data will be collected using a self-administered&#xD;
      questionnaire where socio-demographic characteristics, health-related issues and sexual&#xD;
      behavior will be questioned. Also anal canal sampling will be performed for cytological&#xD;
      analysis. For the HIV infected MSM, additional information will be extracted from the patient&#xD;
      files: CD4+ T-cell count and nadir and duration of combination antiretroviral therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the prevalence of anal high risk HPV infection in MSM using PrEP</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the prevalence of high risk HPV in MSM using PrEP with that of HIV uninfected MSM not using PrEP</measure>
    <time_frame>2 year</time_frame>
    <description>comparation will be done with partially using literature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the prevalence of high risk HPV in MSM using PrEP with that of HIV infected MSM</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the prevalence of abnormal anal cytology in MSM using PrEP and in HIV infected MSM</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>to determine the correlation between abnormal cytology and HPV infection in MSM using PrEP</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To determine possible correlations between the characteristics asked in the questionnaire and the prevalence of high risk HPV infection in both MSM using PrEP and MSM who have HIV</measure>
    <time_frame>2 year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>HAS-N</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm the patient without HIV using PrEP will be included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAS-P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm the patient with HIV will be included</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anal sampling</intervention_name>
    <description>anal sampling will be performed both in men without HIV and men having HIV in order to see if they have HPV or not</description>
    <arm_group_label>HAS-N</arm_group_label>
    <arm_group_label>HAS-P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV uninfected MSM of 18 years or older using PrEP since at least 3 months&#xD;
&#xD;
          -  HIV-infected MSM of 18 years or older&#xD;
&#xD;
        Exclusion Criteria for MSM using PrEP:&#xD;
&#xD;
          -  Any intervention in the (peri-) anal region in the past 3 months&#xD;
&#xD;
          -  enema within 24h before sampling&#xD;
&#xD;
          -  receptive anal sex within 24h before sampling&#xD;
&#xD;
          -  current/ongoing peri-anal topical HPV-treatment&#xD;
&#xD;
        Exclusion Criteria for MSM infected with HPV:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabine Allard</last_name>
    <phone>1923369</phone>
    <email>sabine.allard@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virgini Van Buggenhout</last_name>
    <phone>1925014</phone>
    <email>virgini.vanbuggenhout@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Allard</last_name>
      <phone>1923369</phone>
      <email>sabine.allard@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Virgini Van Buggenhout</last_name>
      <phone>1925014</phone>
      <email>virgini.vanbuggenhout@uzbrussel.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

